Informations générales (source: ClinicalTrials.gov)
Interventional
Phase 3
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
29 juin 2024
Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months in
patients with head and neck squamous cell carcinomas (oral cavity, larynx, oropharynx and
hypopharynx) and with an HADS total score > 11
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Sarah DAUCHY, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Head and neck squamous cell carcinomas, stage I to IVb
2. First-line curative cancer therapy : surgery and/or brachytherapy and/or
chemotherapy
3. HADS- T >11
4. Aged 18 to 75 yo, written consent required
5. OMS>2
1. Head and neck squamous cell carcinomas, stage I to IVb
2. First-line curative cancer therapy : surgery and/or brachytherapy and/or
chemotherapy
3. HADS- T >11
4. Aged 18 to 75 yo, written consent required
5. OMS>2
1. Palliative care
2. Previous head and neck cancer
3. Bipolar disorder or schizophrenia
4. Severe major depressive disorder (DSM-IV TR)
5. Expressed suicidal ideation
6. Severe untreated organic disorder, especially acute infectious disorder
7. ASAT/ALAT > 3N
8. Clearance of creatinin < 30 ml/mn
9. Hyponatremia
10. Antecedent of delirium tremens or acute alcohol withdrawal disorder
11. Antecedent of upper gastro-intestinal bleeding
12. Antecedent of toxicity or inefficacy of a previous treatment with escitalopram
13. Unauthorized treatments :- Antidepressant or antiepileptic (clonazepam authorized)-
Hypnotic except zolpidem - Anxiolytic except clonazepam, clorazepate or diazepam-
bupropion or varenicline
14. Pregnancy or lactation